Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Pancreatic cancer (PC) remains a leading cause of cancer mortality globally.
• Current treatment modalities offer limited efficacy, highlighting the need for novel therapeutic strategies.
• Immune checkpoint inhibitors, particularly targeting PD-1/PD-L1, represent a promising avenue for cancer immunotherapy.

Purpose of the Study:

• To provide an up-to-date review on the role of PD-1 and PD-L1 in pancreatic cancer immune tolerance.
• To summarize current clinical trials, outcomes, and mechanisms of PD-1/PD-L1 signaling in PC.
• To evaluate the safety, tolerance, and efficacy of PD-1/PD-L1 blocking agents and targeted therapeutics for advanced PC.

Main Methods:

• Comprehensive literature review of existing studies on PD-1/PD-L1 in pancreatic cancer.
• Analysis of clinical trial data and reported outcomes for PD-1/PD-L1 inhibitors.
• Review of mechanistic studies investigating PD-1/PD-L1 signaling pathways in PC stem cells and metastasis.

Main Results:

• PD-1/PD-L1 pathways play a critical role in establishing immune tolerance within the pancreatic tumor microenvironment.
• PD-1/PD-L1 signaling contributes to the maintenance of pancreatic cancer stem cells and promotes metastatic progression.
• Clinical trials demonstrate varying efficacy of PD-1/PD-L1 inhibitors, with ongoing research to optimize their use.

Conclusions:

• Understanding PD-1/PD-L1 mechanisms is crucial for developing effective immunotherapies for pancreatic cancer.
• Targeting PD-1/PD-L1 offers potential for managing advanced pancreatic cancer with improved safety and tolerability.
• Further research is needed to refine treatment regimens and predict patient response to PD-1/PD-L1 blockade.